Evidence map›Paper›PMID 30202825›Full record

ArticleHepatology communications2018

Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.

Ronald E Rose, Dennis Hernandez, Paul J Falk, Karen Ericson, Nannan Zhou, Alexandra Thiry, Fiona McPhee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ronald E RoseBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Dennis HernandezBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Paul J FalkBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Karen EricsonBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Nannan ZhouBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Alexandra ThiryBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Fiona McPheeBristol-Myers Squibb Pharmaceutical Research and Development Wallingford CT.
Bristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Entecavir (ETV) is a first-line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV-resistant (ETVr) HBV DNA resulted from substitutions in the HBV reverse transcriptase (RT) at positions rtT184, rtS202, or rtM250 in combination with lamivudine resistance (LVDr) substitutions rtM204I/V±rtL180M.

Identifiers

PMID30202825
PMCPMC6128232
OpenAlexW2888702210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.